AI model helps predict ALS mortality using clinical metrics
Using seven clinical measures that are fairly easy to assess, researchers have developed a machine learning model to help predict…
Articles by Lila Levinson, PhD
Targeting FGF21 hormone may slow ALS disease progression
FGF21, a hormone that helps cells regulate energy use and respond to stress, may protect muscles and nerve cells from…
Model identifies ALS subtypes to help design targeted treatment
Researchers identified three forms, or biotypes, of amyotrophic lateral sclerosis (ALS), each with distinct mechanisms that could suggest pathways…
Coya gets FDA clearance to start Phase 2 trial of ALS treatment
Coya Therapeutics is preparing to launch a Phase 2 clinical trial in the U.S. to test its COYA 302 as…
Healthy volunteer study’s results net clinical trial for ALS therapy
An experimental oral therapy for amyotrophic lateral sclerosis (ALS) that’s being developed by Athira Pharma was shown to…
Inhibiting cellular stress response may help with rare ALS type: Study
For a rare type of amyotrophic lateral sclerosis (ALS), inhibiting a cellular stress response can normalize processes and function…
Toxic dye may cause ALS-like symptoms, neurodegeneration
Being exposed to rhodamine B (RhB), a toxic fluorescent dye, causes neurodegeneration and symptoms that resemble amyotrophic lateral sclerosis…
New collaboration will use AI tools to find ALS treatment targets
A new coalition aims to use artificial intelligence (AI) tools to accelerate drug discovery for amyotrophic lateral sclerosis (ALS)…
Zhimeng cleared to launch study of ALS therapy CB03-154 in China
China’s Center for Drug Evaluation (CDE) has approved a request by Zhimeng Biopharma to launch a Phase 2/3 study…
AMX0114 receives FDA fast track status for the treatment of ALS
The U.S. Food and Drug Administration (FDA) has granted fast track designation to AMX0114, an experimental therapy being developed by…